OPAL:NASDAQOPAL Fuels Inc. Analysis
Data as of 2026-04-22 - not real-time
$2.54
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
OPAL Fuels is trading at $2.54, comfortably above its 20‑day ($2.44) and 50‑day ($2.28) simple moving averages, with the 200‑day SMA ($2.36) also below price, indicating a short‑term bullish bias. The RSI sits at 57.7, well within the neutral‑to‑bullish zone, and the MACD line (+0.07) is just above its signal (+0.06), producing a modest bullish histogram. Volume has been decreasing, and the 30‑day realized volatility is extremely high at ~98%, while a computed beta of 1.69 signals sensitivity to market moves. Market sentiment is at an "Extreme Greed" level (86.6 on the Fear & Greed Index), supporting the upside potential. Fundamentally, revenue grew 24.7% YoY to $349 M and adjusted EBITDA rose to $34.2 M in Q4 2025, with management guiding 2026 EBITDA of $95‑$110 M and RNG production growth of ~14%. However, the balance sheet is strained: debt of $368 M versus cash of $24 M (Debt/Equity ≈ 74%) and a negative free cash flow of $‑59.5 M, while the price‑to‑book ratio is deeply negative at -5.7. The DCF fair value of $3.46 implies a ~26% upside, and the P/E of 16.9 is below the industry average of 22.1, suggesting the stock is currently undervalued.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Price above key moving averages and bullish MACD
- Technical upside to $2.69 resistance and DCF implied upside
- Recent IRA tax‑credit sale boosting cash inflows
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Strong revenue and EBITDA growth guidance for 2026
- High leverage and negative free cash flow constrain flexibility
- Volatility and beta suggest continued price swings
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Undervalued relative to peers and DCF upside
- Secular tailwinds for renewable natural gas and policy incentives
- Potential for balance‑sheet improvement as tax credits are monetized
Key Metrics & Analysis
Financial Health
Revenue Growth24.70%
Profit Margin4.23%
P/E Ratio16.9
ROE7.56%
ROA0.32%
Debt/Equity73.98
P/B Ratio-5.7
Op. Cash Flow$36.5M
Free Cash Flow$-59553752
Industry P/E22.1
Technical Analysis
TrendNeutral
RSI57.7
Support$2.19
Resistance$2.69
MA 20$2.44
MA 50$2.28
MA 200$2.36
MACDBullish
VolumeDecreasing
Fear & Greed Index86.61
Valuation
Fair Value$3.46
Target Price$3.21
Upside/Downside26.32%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.69
Volatility97.52%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.